Bayesian Capital Management’s Pacira BioSciences PCRX Stock Holding History

Bayesian Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,080	Closed	-$408K	–	910
2024 Q3	$408K	Buy	+27,080	New	+$463K	0.05%	418
2019 Q2	–	Sell	-10,000	Closed	-$381K	–	648
2019 Q1	$381K	Buy	+10,000	New	+$390K	0.07%	352
2018 Q1	–	Sell	-14,710	Closed	-$672K	–	759
2017 Q4	$672K	Buy	+14,710	New	+$583K	0.14%	252
2017 Q2	–	Sell	-10,700	Closed	-$488K	–	556
2017 Q1	$488K	Buy	+10,700	New	+$462K	0.23%	169
2016 Q4	–	Sell	-9,350	Closed	-$320K	–	679
2016 Q3	$320K	Buy	+9,350	New	+$366K	0.21%	178

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bayesian Capital Management's PCRX Position: Q4 2024 in Review

Bayesian Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 27,080 shares — an estimated $408K sold.

Bayesian Capital Management first reported a position in PCRX in Q3 2016 and held it in 5 quarters. The position peaked at $672K in Q4 2017. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

Bayesian Capital Management reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
Bayesian Capital Management sold 27,080 Pacira BioSciences shares in Q4 2024, an estimated $408K.
Bayesian Capital Management first reported a position in Pacira BioSciences in Q3 2016 and held it in 5 quarters.
Bayesian Capital Management's Pacira BioSciences position peaked at $672K in Q4 2017.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.